About BiliRecs

About

BiliRecs is a clinical decision support tool based on the 2022 revised guidelines from the American Academy of Pediatrics to provide a framework for the prevention and management of hyperbilirubinemia (or Jaundice) in newborn infants of 35 or more weeks of gestation. The goal of this tool is to reduce the incidence of severe hyperbilirubinemia and bilirubin encephalopathy while minimizing the risks of unintended harm such as maternal anxiety, decreased breastfeeding, and unnecessary costs or treatment.

References

Peer-reviewed journal articles:

Development of a Web-based Decision Support Tool to Increase Use of Neonatal Hyperbilirubinemia Guidelines
Longhurst CA, Turner SW, Burgos AE
Journal of Quality and Patient Safety May 2009

Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation
AAP Subcommittee on Hyperbilirubinemia
Pediatrics August 2022

Clinical Practice Guideline: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation
AAP Subcommittee on Hyperbilirubinemia
Pediatrics July 2004

Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns
Bhutani VK, Johnson L, Sivieri EM
Pediatrics January 1999

Risk Factors for Neurotoxicity in Newborns With Severe Neonatal Hyperbilirubinemia
Gamaleldin R, Iskander I, Seoud I, Aboraya H, Aravkin A, Sampson PD, Wennberg RP
Pediatrics October 2011

Created By

Senior Application Architect Stanford Children's Health
Clinical Associate Professor of Pediatrics Stanford University